1075 HJ Amsterdam
When Wegovy/Zepbound Makes Sense Weight loss medications like Wegovy and Zepbound have a particular use case: typically, patients on the lower end of the obesity scale according to their BMI, which is 30 to 35, would be best served by losing approximately 15 to 25% of their body weight, and this may resolve many of their comorbidities
(Source: Healthline, 2026) The BALANCE Model Has Been Delayed Indefinitely CMS originally announced two programs: the GLP-1 Bridge Program and the BALANCE model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health), a five-year CMS Innovation Center model that would have let Part D plans opt in to covering weight loss GLP-1s starting January 2027
Appetite suppression more noticeable Month 4 (4mg): Additional 5-7 lbs
Final pricing is confirmed at checkout
Apovian CM, Bergenstal RM, Cuddihy RM, et al